ArticleGenes & genomics2020
Comprehensive analysis of the expression and prognosis for TFAP2 in human lung carcinoma.
Article in Genes & genomics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 14 citations in OpenAlex.
- Article
- A review of current developments in RNA modifications in lung cancer.Cancer cell international · 2024Review
- Structural basis for specific DNA sequence motif recognition by the TFAP2 transcription factors.Nucleic acids research · 2023Article
- Drug resistance related genes in lung adenocarcinoma predict patient prognosis and influence the tumor microenvironment.Scientific reports · 2023Article
- Article
- Overexpression of Tfap2a in Mouse Oocytes Impaired Spindle and Chromosome Organization.International journal of molecular sciences · 2022Article
- Transcription factor AP2 enhances malignancy of non-small cell lung cancer through upregulation of USP22 gene expression.Cell communication and signaling : CCS · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe TFAP2 family of transcription factors, regulating gene expression related to vertebrate evolution, have been studied extensively in human cancer. However, the distinct roles of each TFAP2 in the expression and prognostic significance of lung carcinoma have not been elucidated yet.
objectiveThis study is aimed to identify the mRNA expression and prognostic value of TFAP2 family in human lung cancer.
methodsThe transcriptional and survival data of TFAP2s in patients with lung cancer were obtained via ONCOMINE, LinkedOmics, GEPIA, cBioPortal, Kaplan-Meier Plotter and Human Protein Atlas databases.
resultsThe results showed that expression levels of TFAP2A and TFAP2C were higher in lung adenocarcinoma and squamous cell carcinoma tissues than in normal lung tissues, whereas no difference was found in the TFAP2B expression level. TFAP2A was related to an unfavorable overall survival in lung cancer and its upregulation was significantly related to the overall survival in patients with smoking, non-chemotherapy and non-radiotherapy.
conclusionThis study implied that TFAP2A was a reliable prognostic factor, which could be a potential marker for improving survival and prognostic accuracy of lung cancer patients.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.